AVI BioPharma To Present Safety Update From Ongoing Systemic Trial Of AVI-4658 At 7th Annual Action Duchenne International Conference

October 23 2009

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced that it will present updated preliminary safety data from its ongoing systemic Phase 1b/2 clinical trial of AVI-4658 in patients with Duchenne muscular dystrophy (DMD) at the 7th Annual Action Duchenne Conference taking place Oct. 23-24 in London, UK. Steve Shrewsbury, M.D...

  • Donate
  • Congenital Muscular Dystrophy

    A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...
  • Register Now!
  • Events

  • Register Now!
  • Navigation

    Show Sub-Pages | Hide Sub-Pages